IBTK and myeloid sarcoma: These observations complement elegant recent animal model work showing that treatment with BTKi decreases B-cell costimulatory molecule expression and limits B-cell APC function in experimental autoimmune encephalomyelitis, the commonly used animal model of MS [52].